PE-conjugated Anti-PD-L1(avelumab biosimilar) mAb Cat. No. BME100418P



## **PRODUCT INFORMATION**

Common Name	BAVENCIO;MSB-0010718C;MSB0010718;CPF-06834635;CPF06834635
Synonyms	B7-H;B7H1;PDL1;PD-L1;PDCD1L1;PDCD1LG1
Applications	Flow Cyt
Recommended Dilutions	Flow Cyt 1:100
Formulation & Reconstitution	Liquid_PBS with 0.05% Proclin300, 1% BSA
Host Species	N/A
lgG type	lgG1
Reactivity	Human
Target	PD-L1
Uniprot ID	Q9NZQ7
Description	PE-conjugated Anti-PD-L1(avelumab biosimilar) mAb
Delivery	6-8 weeks
Storage & Shipping	Store at 2°C-8°C for 6 months
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only
Conjugate	PE-conjugated
DIMA Disclaimer	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.

Address: Wuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China Telephone: +1 2409940618(USA) /+86-18062749453(China) /+86-400-006-0995(China)

Email: info@dimabio.com Website: www.dimabio.com

